Andres Liivak is a partner in White & Case's Global Mergers & Acquisitions and Global Technology Transaction Practices, based in New York. Andres is also a member of the firm's Global Pharmaceuticals & Healthcare Industry Group.
Andres' practice focuses on structuring and negotiating complex agreements worldwide for the life sciences industry involving pharmaceutical, biotech and medical device products and services, as well as emerging advanced health technologies including numerous digital transformation deals.
Andres regularly represents the world's largest multi-national pharmaceutical companies, mid-size Japanese, European and Indian pharmaceutical companies and global medical device companies. He also advises global tech companies that are becoming increasingly involved in the healthcare and life sciences sectors. Andres' extensive experience in both life sciences and digital health technology provides him with a unique working knowledge of the special combinations of technical, regulatory and commercialization challenges present in "digital" deals in life sciences.
Representative matters include:
CM Life Sciences III (NASDAQ: CMLT), a SPAC sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, in its US$3.65 billion business combination with EQRx, Inc.
CM Life Sciences (NASDAQ: CMLF), a SPAC sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, in its US$2 billion business combination with Mount Sinai Genomics, Inc. d/b/a Sema4.
HighCape Capital Acquisition Corp. (NASDAQ: CAPA), a SPAC sponsored by HighCape Capital LP, a healthcare growth equity fund, in its US$1.46 billion business combination with Quantum-Si Incorporated, a pioneer in next generation semiconductor chip-based proteomics.
An affiliate of Morgan Stanley Infrastructure in its US$1.3 billion acquisition of SpecialtyCare, Inc., a leading national platform with an established network for providing outsourced clinical services to hospital operating rooms and provider of perfusion, intraoperative neuromonitoring and surgical services.
Electric commercial vehicle company VIA Motors International, Inc. on its acquisition (in an all-stock merger valued at up to US$630 million) by Ideanomics, Inc., a global company focused on driving the adoption of commercial electric vehicles and associated energy consumption.
Helix Acquisition Corp. (NASDAQ: HLXA), a SPAC, in its US$230 million business combination with MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases.
QH Oil Investments LP, an affiliate of Qatar Investment Authority, on its investment in the US$230 million Series B fundraising of Tessera Therapeutics, Inc., an early-stage life sciences company founded by Flagship Pioneering that is pioneering Gene Writing, which was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2.
BVCF Management Ltd., China's first US dollar fund that focuses on life sciences and healthcare, in its US$15 million investment in Cellenkos Inc., a US-based early stage clinical biotechnology company that focuses on umbilical cord blood derived T-regulatory cellular therapies for treating autoimmune diseases and inflammatory disorders.
Biosight Ltd., a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, in its reverse merger transaction with Advaxis, Inc. (NASDAQ: ADXS), pursuant to which the shareholders of Biosight will become the majority holders of the combined company immediately following completion of the transaction.
Cobepa S.A. in the acquisition of MicroConstants Inc., a San Diego-based contract research organization, by BioAgilytix Labs, LLC, a portfolio company of Cobepa.
The Carlyle Group European Technology Fund IV in its acquisition of LiveU, an Israeli-headquartered producer of portable cellular backpacks for video streaming and live broadcasting from Francisco Partners, the majority shareholder and minority shareholders.
Representative matters prior to joining White & Case include:.
A multinational pharmaceutical company in its US$1 billion+ option in-license deal for development stage drug candidate.
A multinational medical device company in its in-license of certain technologies for use in its development stage medical devices.
A leading tech company's digital health business in its entity joint venture with a market-leading medical device company.
A multinational pharmaceutical and medical device company in its US$10 billion+ divestment of a major division of the company.
A multinational pharmaceutical company in its license and commercialization arrangements for an FDA approved therapeutic mobile medical app.
A leading tech company's digital health business in discovery collaborations with leading biotechnology companies, including involving the deployment of machine learning and other cutting-edge digital technologies.
A multinational pharmaceutical and medical device company in its US$200 million asset divestment of its dermatology drug business.
A Japanese pharmaceutical company in its co-commercialization arrangements for its Phase III drug candidate just prior to approval.
A Japanese pharmaceutical company in its in-license arrangements for the European commercialization of a Phase III oncology drug.
A multinational pharmaceutical and medical device company in its litigation settlement and renegotiation of licensing arrangements relating to one of its leading product franchises.
A multinational joint venture in its US$1 billion+ asset acquisition of certain development stage drug candidates.
A Japanese pharmaceutical company in its risk sharing development and commercialization arrangements with a major biotechnology company for certain high profile development stage drugs.
A multinational pharmaceutical company in its therapeutic area risk sharing arrangements with a biotechnology company for development stage and marketed drugs in a therapeutic area.
A pharmaceutical company in its U.S. Bankruptcy Code Section 363 "Stalking Horse" bid and asset acquisition of marketed pharmaceutical product assets.
A multinational pharmaceutical company in its "OTC-switch" in-license transaction for drug.
A multinational pharmaceutical company in its multi-billion dollar worldwide cross-license and settlement arrangements with another multinational pharmaceutical company regarding their respective blockbuster, high-profile drugs.
Legal 500 USA, recommended lawyer, Industry focus - Healthcare: life sciences, Legal 500, 2016-2018
Legal 500 USA, recommended lawyer, M&A/corporate and commercial - M&A - middle-market (US$500m-999m), Legal 500, 2016
Life Science Star, Non-IP Litigation: Mergers & Acquisitions, LMG Life Sciences, 2015 - 2016, 2018
Highly regarded lawyer - Debt Capital Markets, Structured Finance and Securitisation, IFLR1000 2018